Protective effects of methyl palmitate against silica-induced pulmonary fibrosis in rats

Maha H. Sharawy, Dina S. El-Agamy, Asem A. Shalaby, El Sayed M Ammar

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Silicosis is one of the most prevalent chronic occupational pulmonary diseases worldwide. The present study aimed to investigate the effects of methyl palmitate on silica-induced lung fibrosis in rats and explore the possible mechanisms. Male Sprague-Dawley rats were divided into 3 groups: group I served as control and group II served as positive control where rats were intranasally instilled with a single dose of silica suspension (50 mg in 0.1 ml saline/rat). Rats of group III received methyl palmitate (300 mg/kg, I.P. three times per week at alternating days) for 60 days after instillation of silica. At the end of the treatment period, animals were sacrificed then biochemical parameters and histopathology were assessed. Treatment with methyl palmitate attenuated silica-induced lung inflammation and fibrosis, as it significantly decreased lactate dehydrogenase (LDH) activity and the accumulation of the inflammatory cells in the bronchoalveolar lavage fluid (BALF). Methyl palmitate significantly reduced collagen deposition as indicated by a decrease in lung hydroxyproline content and marked attenuation in silica-induced lung fibrosis in histopathological results. In addition, methyl palmitate significantly increased superoxide dismutase (SOD) and reduced glutathione (GSH) activities with a significant decrease in the lung malondialdehyde (MDA) content. Methyl palmitate also reduced silica mediated overproduction of pulmonary nitrite/nitrate (NO2 -/NO3 -). Importantly, methyl palmitate decreased the level of the inflammatory cytokine tumor necrosis factor-alpha (TNF-α) in the lung. Taken together, these results demonstrate the potent protective effects of methyl palmitate against silica-induced lung fibrosis. This effect can be attributed to methyl palmitate's ability to counteract the inflammatory cells' infiltration and hence reactive oxygen species (ROS) generation and regulate cytokine effects.

Original languageEnglish
Pages (from-to)191-198
Number of pages8
JournalInternational Immunopharmacology
Volume16
Issue number2
DOIs
Publication statusPublished - Jun 2013

Fingerprint

Pulmonary Fibrosis
Silicon Dioxide
Lung
Fibrosis
Cytokines
methyl palmitate
Silicosis
Occupational Diseases
Hydroxyproline
Bronchoalveolar Lavage Fluid
Nitrites
Malondialdehyde
L-Lactate Dehydrogenase
Nitrates
Lung Diseases
Superoxide Dismutase
Glutathione
Sprague Dawley Rats
Reactive Oxygen Species
Pneumonia

Keywords

  • Methyl palmitate
  • Oxidative stress
  • Pulmonary fibrosis
  • Rats
  • Silica

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy
  • Pharmacology

Cite this

Protective effects of methyl palmitate against silica-induced pulmonary fibrosis in rats. / Sharawy, Maha H.; El-Agamy, Dina S.; Shalaby, Asem A.; Ammar, El Sayed M.

In: International Immunopharmacology, Vol. 16, No. 2, 06.2013, p. 191-198.

Research output: Contribution to journalArticle

Sharawy, Maha H. ; El-Agamy, Dina S. ; Shalaby, Asem A. ; Ammar, El Sayed M. / Protective effects of methyl palmitate against silica-induced pulmonary fibrosis in rats. In: International Immunopharmacology. 2013 ; Vol. 16, No. 2. pp. 191-198.
@article{00ef33d824174a71a273b0966ea65c87,
title = "Protective effects of methyl palmitate against silica-induced pulmonary fibrosis in rats",
abstract = "Silicosis is one of the most prevalent chronic occupational pulmonary diseases worldwide. The present study aimed to investigate the effects of methyl palmitate on silica-induced lung fibrosis in rats and explore the possible mechanisms. Male Sprague-Dawley rats were divided into 3 groups: group I served as control and group II served as positive control where rats were intranasally instilled with a single dose of silica suspension (50 mg in 0.1 ml saline/rat). Rats of group III received methyl palmitate (300 mg/kg, I.P. three times per week at alternating days) for 60 days after instillation of silica. At the end of the treatment period, animals were sacrificed then biochemical parameters and histopathology were assessed. Treatment with methyl palmitate attenuated silica-induced lung inflammation and fibrosis, as it significantly decreased lactate dehydrogenase (LDH) activity and the accumulation of the inflammatory cells in the bronchoalveolar lavage fluid (BALF). Methyl palmitate significantly reduced collagen deposition as indicated by a decrease in lung hydroxyproline content and marked attenuation in silica-induced lung fibrosis in histopathological results. In addition, methyl palmitate significantly increased superoxide dismutase (SOD) and reduced glutathione (GSH) activities with a significant decrease in the lung malondialdehyde (MDA) content. Methyl palmitate also reduced silica mediated overproduction of pulmonary nitrite/nitrate (NO2 -/NO3 -). Importantly, methyl palmitate decreased the level of the inflammatory cytokine tumor necrosis factor-alpha (TNF-α) in the lung. Taken together, these results demonstrate the potent protective effects of methyl palmitate against silica-induced lung fibrosis. This effect can be attributed to methyl palmitate's ability to counteract the inflammatory cells' infiltration and hence reactive oxygen species (ROS) generation and regulate cytokine effects.",
keywords = "Methyl palmitate, Oxidative stress, Pulmonary fibrosis, Rats, Silica",
author = "Sharawy, {Maha H.} and El-Agamy, {Dina S.} and Shalaby, {Asem A.} and Ammar, {El Sayed M}",
year = "2013",
month = "6",
doi = "10.1016/j.intimp.2013.04.007",
language = "English",
volume = "16",
pages = "191--198",
journal = "International Immunopharmacology",
issn = "1567-5769",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Protective effects of methyl palmitate against silica-induced pulmonary fibrosis in rats

AU - Sharawy, Maha H.

AU - El-Agamy, Dina S.

AU - Shalaby, Asem A.

AU - Ammar, El Sayed M

PY - 2013/6

Y1 - 2013/6

N2 - Silicosis is one of the most prevalent chronic occupational pulmonary diseases worldwide. The present study aimed to investigate the effects of methyl palmitate on silica-induced lung fibrosis in rats and explore the possible mechanisms. Male Sprague-Dawley rats were divided into 3 groups: group I served as control and group II served as positive control where rats were intranasally instilled with a single dose of silica suspension (50 mg in 0.1 ml saline/rat). Rats of group III received methyl palmitate (300 mg/kg, I.P. three times per week at alternating days) for 60 days after instillation of silica. At the end of the treatment period, animals were sacrificed then biochemical parameters and histopathology were assessed. Treatment with methyl palmitate attenuated silica-induced lung inflammation and fibrosis, as it significantly decreased lactate dehydrogenase (LDH) activity and the accumulation of the inflammatory cells in the bronchoalveolar lavage fluid (BALF). Methyl palmitate significantly reduced collagen deposition as indicated by a decrease in lung hydroxyproline content and marked attenuation in silica-induced lung fibrosis in histopathological results. In addition, methyl palmitate significantly increased superoxide dismutase (SOD) and reduced glutathione (GSH) activities with a significant decrease in the lung malondialdehyde (MDA) content. Methyl palmitate also reduced silica mediated overproduction of pulmonary nitrite/nitrate (NO2 -/NO3 -). Importantly, methyl palmitate decreased the level of the inflammatory cytokine tumor necrosis factor-alpha (TNF-α) in the lung. Taken together, these results demonstrate the potent protective effects of methyl palmitate against silica-induced lung fibrosis. This effect can be attributed to methyl palmitate's ability to counteract the inflammatory cells' infiltration and hence reactive oxygen species (ROS) generation and regulate cytokine effects.

AB - Silicosis is one of the most prevalent chronic occupational pulmonary diseases worldwide. The present study aimed to investigate the effects of methyl palmitate on silica-induced lung fibrosis in rats and explore the possible mechanisms. Male Sprague-Dawley rats were divided into 3 groups: group I served as control and group II served as positive control where rats were intranasally instilled with a single dose of silica suspension (50 mg in 0.1 ml saline/rat). Rats of group III received methyl palmitate (300 mg/kg, I.P. three times per week at alternating days) for 60 days after instillation of silica. At the end of the treatment period, animals were sacrificed then biochemical parameters and histopathology were assessed. Treatment with methyl palmitate attenuated silica-induced lung inflammation and fibrosis, as it significantly decreased lactate dehydrogenase (LDH) activity and the accumulation of the inflammatory cells in the bronchoalveolar lavage fluid (BALF). Methyl palmitate significantly reduced collagen deposition as indicated by a decrease in lung hydroxyproline content and marked attenuation in silica-induced lung fibrosis in histopathological results. In addition, methyl palmitate significantly increased superoxide dismutase (SOD) and reduced glutathione (GSH) activities with a significant decrease in the lung malondialdehyde (MDA) content. Methyl palmitate also reduced silica mediated overproduction of pulmonary nitrite/nitrate (NO2 -/NO3 -). Importantly, methyl palmitate decreased the level of the inflammatory cytokine tumor necrosis factor-alpha (TNF-α) in the lung. Taken together, these results demonstrate the potent protective effects of methyl palmitate against silica-induced lung fibrosis. This effect can be attributed to methyl palmitate's ability to counteract the inflammatory cells' infiltration and hence reactive oxygen species (ROS) generation and regulate cytokine effects.

KW - Methyl palmitate

KW - Oxidative stress

KW - Pulmonary fibrosis

KW - Rats

KW - Silica

UR - http://www.scopus.com/inward/record.url?scp=84877817503&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877817503&partnerID=8YFLogxK

U2 - 10.1016/j.intimp.2013.04.007

DO - 10.1016/j.intimp.2013.04.007

M3 - Article

VL - 16

SP - 191

EP - 198

JO - International Immunopharmacology

JF - International Immunopharmacology

SN - 1567-5769

IS - 2

ER -